Characteristics
Total (n=307)
Amiodarone failure (n=124)
Amiodarone Success (n=183)
p-value
Age (years) 67 (60-73) 67 (58 -71.7) 68 (61 -74) 0.07
White, n (%) 272 (88.6) 112 (90.3) 160 (87.4) 0.93
Male, n (%) 217 (70.7) 88 (71) 129 (70.5) 0.92
Body mass index (kg/m2) 29.8 (26.4 -34.2) 29.7 (26.3 – 34.3) 29.9 (26.4 -34) 0.91
Duration of AF (years) 3 (2 – 7) 3.5 (2–7) 3 (1.5 –6) 0.47
Duration of amiodarone therapy pre-ablation, years (months) 5 (3 – 15) 5 (2.2-13.7) 6 (3 -16) 0.42
AF type 0.03
Paroxysmal AF, n (%) 146 (47.6) 50 (40.3) 96 (52.5)
Persistent AF, n (%) 161 (52.4) 74 (59.7) 87 (47.5)
Congestive heart failure, n (%) 74 (24.1) 34 (27.4) 40 (21.9) 0.26
Hypertension, n (%) 207 (67.4) 80 (64.5) 127 (69.4) 0.37
Diabetes mellitus, n (%) 53 (17.3) 15 (12.1) 38 (20.8) 0.04
Stroke/TIA, n (%) 33 (10.7) 15 (12.1) 18 (9.8) 0.53
CHA2DS2-VASc score 2.0 (1.0 -3.0) 2 (1 – 3) 2.5 (2 – 4) 0.18
Obstructive sleep apnea, n (%) 56 (18.2) 31 (25) 25 (13.7) 0.01
Chronic kidney disease, n (%) 42 (13.7) 17 (13.7) 25 (13.7) 0.99
Hyperlipidemia, n (%) 133 (43.3) 56 (45.2) 77 (42.1) 0.59
Asthma/COPD, n (%) 22 (7.2) 8 (6.5) 14 (7.7) 0.68
Smoking history, n (%) 98 (32) 36 (29) 62 (34.1) 0.35
ACE inhibitor, n (%) 77 (25.2) 35 (28.5) 42 (23) 0.27
Angiotensin II receptor blocker, n (%) 65 (21.2) 24 (19.4) 41 (22.4) 0.52
Beta blocker/ Calcium channel blocker, n (%) 251 (81.8) 107 (86.3) 144 (78.7) 0.09
Statin, n (%) 156 (51) 64 (52) 92 (50.3) 0.76
Anticoagulation 0.06
None, n (%) 7 (2.3) 0 (0) 7 (3.8)
Coumadin, n (%) 68 (22.1) 31 (25) 37 (20.2)
Direct oral anticoagulant, n (%) 232 (75.6) 93 (75) 139 (76)
LA diameter by TTE (cm) 4.4 (4.0-5.0) 4.5 (4.0-5.0) 4.3 (4.0- 5.0) 0.73
LV ejection fraction by TTE (%) 55 (50 – 60) 55 (50 -60) 55 (50 -60) 0.64